RU2007139915A - Haemophilus influenzae типа в - Google Patents
Haemophilus influenzae типа в Download PDFInfo
- Publication number
- RU2007139915A RU2007139915A RU2007139915/13A RU2007139915A RU2007139915A RU 2007139915 A RU2007139915 A RU 2007139915A RU 2007139915/13 A RU2007139915/13 A RU 2007139915/13A RU 2007139915 A RU2007139915 A RU 2007139915A RU 2007139915 A RU2007139915 A RU 2007139915A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- polypeptide
- seq
- antibody
- composition
- Prior art date
Links
- 241000606768 Haemophilus influenzae Species 0.000 title claims 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 claims abstract 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract 17
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 17
- 229920001184 polypeptide Polymers 0.000 claims abstract 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 239000012634 fragment Substances 0.000 claims abstract 6
- 239000002773 nucleotide Substances 0.000 claims abstract 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000012646 vaccine adjuvant Substances 0.000 claims abstract 2
- 229940124931 vaccine adjuvant Drugs 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Materials For Photolithography (AREA)
- Developing Agents For Electrophotography (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66792105P | 2005-03-30 | 2005-03-30 | |
| US60/667,921 | 2005-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007139915A true RU2007139915A (ru) | 2009-05-10 |
Family
ID=37087506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007139915/13A RU2007139915A (ru) | 2005-03-30 | 2006-03-30 | Haemophilus influenzae типа в |
Country Status (11)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| CN103052400B (zh) | 2010-07-06 | 2016-11-16 | 诺华股份有限公司 | 自我复制rna分子的病毒样递送颗粒 |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のｒｎａを用いた大型哺乳動物の免疫化 |
| WO2012031046A2 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipids suitable for liposomal delivery of protein-coding rna |
| LT4066856T (lt) | 2010-08-31 | 2023-01-25 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| KR20140066126A (ko) * | 2011-05-11 | 2014-05-30 | 리스벡 헬스케어 스웨덴 에이비 | 단백질 f - 라미닌 및 비트로넥틴 결합 특성을 갖는 신규한 헤모필러스 인플루엔자 부착분자 |
| CA2840977A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
| ES2656050T3 (es) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
| PL2750707T3 (pl) | 2011-08-31 | 2019-05-31 | Glaxosmithkline Biologicals Sa | Pegylowane liposomy do dostarczania rna kodującego immunogen |
| WO2014044728A1 (en) | 2012-09-18 | 2014-03-27 | Novartis Ag | Outer membrane vesicles |
| EA201891018A1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
| AR090303A1 (es) * | 2013-03-11 | 2014-11-05 | Consejo Nac Invest Cient Tec | Polipeptido mutado, cepa de bacterias que lo comprende y metodos para detectar diferentes cationes metalicos simultaneamente |
| BR112015030892A2 (pt) | 2013-06-10 | 2017-08-29 | Merck Sharp & Dohme | Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno |
| ES2774968T3 (es) | 2013-12-19 | 2020-07-23 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201508860D0 (en) | 2015-05-22 | 2015-07-01 | Nat Univ Ireland | Diagnostic method |
| US11401520B2 (en) | 2016-10-21 | 2022-08-02 | The Research Foundation For The State University Of New York | Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US20220143168A1 (en) * | 2019-02-27 | 2022-05-12 | Evaxion Biotech A/S | Vaccines targeting H. influenzae |
| GB2599573A (en) * | 2019-05-31 | 2022-04-06 | Rhogen Biotech Llc | Compositions and methods for detoxifying bacterial endotoxins |
| US11357845B2 (en) * | 2019-07-08 | 2022-06-14 | The Trustees Of The University Of Pennsylvania | Protein antigens for vaccinating against nontypeable Haemophilus influenzae |
| EP4237577A4 (en) * | 2020-10-30 | 2025-01-01 | Gen-Probe Incorporated | COMPOSITIONS AND METHODS FOR THE DETECTION OF INFLUENZA A, INFLUENZA B AND SARS-COV-2 |
| EP4387597A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| EP4387596A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355450B1 (en) * | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
| GB9513074D0 (en) * | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
| US6593114B1 (en) * | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| US6914131B1 (en) * | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| US6730827B1 (en) * | 1998-07-14 | 2004-05-04 | E. I. Du Pont De Nemours And Company | Genes encoding plant adenosine 5′-phosphosulfate reductase |
| US7365185B2 (en) * | 2000-07-19 | 2008-04-29 | Monsanto Technology Llc | Genomic plant sequences and uses thereof |
| WO2001070955A2 (en) * | 2000-03-21 | 2001-09-27 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| EP1601688A2 (en) * | 2003-03-06 | 2005-12-07 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| GB0315022D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Virulence-associated adhesins |
| GB0410866D0 (en) * | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| CA2871088A1 (en) * | 2005-06-16 | 2006-12-28 | Lauren O. Bakaletz | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
-
2006
- 2006-03-30 NZ NZ562381A patent/NZ562381A/en not_active IP Right Cessation
- 2006-03-30 EP EP06758272.6A patent/EP1871888A4/en not_active Withdrawn
- 2006-03-30 WO PCT/US2006/012606 patent/WO2006110413A2/en active Application Filing
- 2006-03-30 AU AU2006235045A patent/AU2006235045A1/en not_active Abandoned
- 2006-03-30 JP JP2008504533A patent/JP2008538183A/ja active Pending
- 2006-03-30 MX MX2007012057A patent/MX2007012057A/es unknown
- 2006-03-30 RU RU2007139915/13A patent/RU2007139915A/ru not_active Application Discontinuation
- 2006-03-30 CA CA002602665A patent/CA2602665A1/en not_active Abandoned
- 2006-03-30 US US11/887,712 patent/US20100034822A1/en not_active Abandoned
- 2006-03-30 CN CN200680018203A patent/CN101687025A/zh active Pending
- 2006-03-30 NZ NZ591415A patent/NZ591415A/xx not_active IP Right Cessation
- 2006-03-30 BR BRPI0609460-0A patent/BRPI0609460A2/pt not_active IP Right Cessation
-
2011
- 2011-12-21 US US13/333,815 patent/US20120093868A1/en not_active Abandoned
-
2014
- 2014-06-19 US US14/309,829 patent/US20140302078A1/en not_active Abandoned
-
2015
- 2015-10-06 US US14/876,623 patent/US20160024157A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008538183A (ja) | 2008-10-16 |
| US20160024157A1 (en) | 2016-01-28 |
| EP1871888A4 (en) | 2013-08-21 |
| AU2006235045A1 (en) | 2006-10-19 |
| WO2006110413A9 (en) | 2010-01-14 |
| NZ591415A (en) | 2012-10-26 |
| US20120093868A1 (en) | 2012-04-19 |
| WO2006110413A2 (en) | 2006-10-19 |
| CN101687025A (zh) | 2010-03-31 |
| BRPI0609460A2 (pt) | 2010-04-13 |
| MX2007012057A (es) | 2007-11-23 |
| US20140302078A1 (en) | 2014-10-09 |
| CA2602665A1 (en) | 2006-10-19 |
| NZ562381A (en) | 2011-06-30 |
| US20100034822A1 (en) | 2010-02-11 |
| EP1871888A2 (en) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007139915A (ru) | Haemophilus influenzae типа в | |
| RU2009102815A (ru) | Полипептиды из neisseria meningitidis | |
| RU2006144093A (ru) | Полипептиды нетипируемой haemophilus influenzae | |
| JP2008538183A5 (enrdf_load_stackoverflow) | ||
| JP2008525033A5 (enrdf_load_stackoverflow) | ||
| JP2003527079A5 (enrdf_load_stackoverflow) | ||
| MX349481B (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. | |
| JP2008508859A5 (enrdf_load_stackoverflow) | ||
| MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
| JP2010166916A5 (enrdf_load_stackoverflow) | ||
| CA2438080A1 (en) | Gonococcal proteins and nucleic acids | |
| JP2010512792A5 (enrdf_load_stackoverflow) | ||
| RU2012139432A (ru) | Полипептиды | |
| RU2002117308A (ru) | 85 кДа АНТИГЕН NEISSERIA | |
| RU2004121149A (ru) | Иммунизация против chlamydia trachomatis | |
| JP2008529558A5 (enrdf_load_stackoverflow) | ||
| JP6505110B2 (ja) | ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用 | |
| MX2009006760A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas. | |
| EP2292648A3 (en) | Small Streptococcus pyogenes antigens and their use | |
| JP2023015301A5 (enrdf_load_stackoverflow) | ||
| JP2013523718A5 (enrdf_load_stackoverflow) | ||
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| RU2010130338A (ru) | Мутантные формы стрептолизина о | |
| ES2551699T3 (es) | Composiciones, procedimientos y kits | |
| RU2014138418A (ru) | Белки пилей и композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120111 |